EVOK - Evoke Pharma, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Evoke Pharma, Inc.

420 Stevens Avenue
Suite 370
Solana Beach, CA 92075
United States

IndustryDrugs - Generic
Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Mr. Cam L. GarnerCo-Founder & Chairperson42.5kN/A1948
Mr. David A. Gonyer R.Ph.Chief Exec. Officer, Pres & Director631.95kN/A1964
Mr. Matthew J. D'Onofrio MBACo-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec.491kN/A1970
Dr. Marilyn R. Carlson D.M.D., M.D., RAC.Chief Medical Officer423.5kN/A1948
Dr. Wayne Alves Ph.D.Sr. Director of Clinical OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.

Corporate Governance

Evoke Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.